Defunct Company
Total Trials
13
As Lead Sponsor
9
As Collaborator
4
Total Enrollment
762
NCT01417000
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
Phase: Phase 2
Role: Lead Sponsor
Start: Sep 21, 2011
Completion: Feb 10, 2017
NCT01967758
Phase I Study of Safety and Immunogenicity of ADU-623
Phase: Phase 1
Role: Collaborator
Start: Jan 8, 2014
Completion: Aug 15, 2018
NCT02004262
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
Start: Feb 5, 2014
Completion: Aug 23, 2016
NCT01675765
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
Start: Sep 3, 2014
Completion: Aug 19, 2019
NCT02243371
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
Start: Jan 2, 2015
Completion: Jul 21, 2017
NCT02575807
Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer
Phase: Phase 1/2
Start: Mar 8, 2016
Completion: May 8, 2018
NCT03189030
Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer
Start: May 2, 2017
Completion: Sep 2, 2020
NCT03175172
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
Start: May 31, 2017
Completion: Jan 31, 2018
NCT03122548
Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers
Start: Aug 14, 2017
NCT03190265
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
Start: Dec 14, 2017
Completion: Aug 23, 2023
NCT03674502
Safety of ADU-1604 in Adults With Metastatic Melanoma
Start: Nov 8, 2018
Completion: Aug 9, 2019
NCT03376477
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
Start: Sep 23, 2019
Completion: May 30, 2025
NCT06197568
Open-Label Study of Vaginal AZU-101 in Postmenopausal Women
Start: May 1, 2026
Completion: Jun 30, 2027